Schrauf Sabrina, Tschismarov Roland, Tauber Erich, Ramsauer Katrin
Themis Bioscience GmbH, Vienna, Austria.
Front Immunol. 2020 Apr 9;11:592. doi: 10.3389/fimmu.2020.00592. eCollection 2020.
Arboviruses represent major challenges to public health, particularly in tropical, and subtropical regions, and a substantial risk to other parts of the world as respective vectors extend their habitats. In recent years, two viruses transmitted by Aedes mosquitoes, Chikungunya and Zika virus, have gathered increased interest. After decades of regionally constrained outbreaks, both viruses have recently caused explosive outbreaks on an unprecedented scale, causing immense suffering and massive economic burdens in affected regions. Chikungunya virus causes an acute febrile illness that often transitions into a chronic manifestation characterized by debilitating arthralgia and/or arthritis in a substantial subset of infected individuals. Zika infection frequently presents as a mild influenza-like illness, often subclinical, but can cause severe complications such as congenital malformations in pregnancy and neurological disorders, including Guillain-Barré syndrome. With no specific treatments or vaccines available, vector control remains the most effective measure to manage spread of these diseases. Given that both viruses cause antibody responses that confer long-term, possibly lifelong protection and that such responses are cross-protective against the various circulating genetic lineages, the development of Zika and Chikungunya vaccines represents a promising route for disease control. In this review we provide a brief overview on Zika and Chikungunya viruses, the etiology and epidemiology of the illnesses they cause and the host immune response against them, before summarizing past and current efforts to develop vaccines to alleviate the burden caused by these emerging diseases. The development of the urgently needed vaccines is hampered by several factors including the unpredictable epidemiology, feasibility of rapid clinical trial implementation during outbreaks and regulatory pathways. We will give an overview of the current developments.
虫媒病毒对公共卫生构成重大挑战,特别是在热带和亚热带地区,而且随着相应病媒扩大其栖息地,对世界其他地区也构成重大风险。近年来,两种由伊蚊传播的病毒——基孔肯雅病毒和寨卡病毒,引起了越来越多的关注。在经历了数十年局部爆发后,这两种病毒最近都以前所未有的规模引发了爆发式疫情,给受影响地区带来了巨大痛苦和沉重经济负担。基孔肯雅病毒会引发急性发热疾病,在相当一部分感染者中,这种疾病往往会转变为以使人衰弱的关节痛和/或关节炎为特征的慢性症状。寨卡病毒感染通常表现为类似流感的轻症,常常是亚临床的,但可能导致严重并发症,如孕期先天性畸形以及包括格林-巴利综合征在内的神经系统疾病。由于没有特效治疗方法或疫苗,病媒控制仍然是管理这些疾病传播的最有效措施。鉴于这两种病毒都会引发能提供长期、甚至可能是终身保护的抗体反应,而且这种反应具有交叉保护作用,能抵御各种流行的基因谱系,因此开发寨卡和基孔肯雅疫苗是控制疾病的一条有前景的途径。在本综述中,我们简要概述了寨卡病毒和基孔肯雅病毒、它们所引发疾病的病因和流行病学以及宿主对它们的免疫反应,然后总结过去和当前为开发疫苗以减轻这些新出现疾病所造成负担而做出的努力。开发急需的疫苗受到多种因素的阻碍,包括不可预测的流行病学情况、疫情爆发期间快速开展临床试验的可行性以及监管途径。我们将概述当前的进展情况。